GLP-1glp-1obesityamylinprecision medicine

Review maps three-level framework for variable GLP-1 response in obesity

Obesity Pillars authors say appetite, reward, metabolic and energy-conservation phenotypes are plausible but not yet validated predictors of treatment effect.

By Maren Holt · Senior Reporter, GLP-1

Oct 6 20:00 ETSource: Obesity pillars

The wire

01A structured literature review in Obesity Pillars integrates pharmacokinetic exposure, receptor-level signalling and central nervous system involvement into a three-level model of GLP-1 receptor agonist response.
02The authors map GIP, amylin and glucagon pathways onto candidate biological domains, offering clinicians a hypothesis for why weight-loss response varies so widely between patients.
03Evidence that these phenotypes predict differential treatment effects is currently insufficient; prospective phenotype-by-treatment interaction studies are needed before any clinical use.

From the source

Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity
Obesity pillars · 2026 Dec · Ghosal S et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42898214/